Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03309579 · ClinicalTrials.gov registry record · NA

SAHaRA: A Randomized Controlled Trial

A NA study, sponsored by Ottawa Hospital Research Institute.

Completed
Registry status
NA
Development phase
742
Enrollment target

NCT03309579 is a NA study that has completed, run by Ottawa Hospital Research Institute. The registered enrollment target is 742 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03309579, a NA study, has completed, sponsored by Ottawa Hospital Research Institute.

COMPLETED
Registry status
NA
Development phase
742 participants
Enrollment target

Study Summary

The SAHaRA trial will clarify the role of treating anemia with Red Blood Cell (RBC) transfusion in a unique and vulnerable patient population, and determine whether that impacts on functional outcomes and mortality. It will guide best practice standards and clarify the optimal RBC transfusion strategy in patients with aSAH.

Interventions

  • OTHER Liberal RBC Transfusion Strategy
  • OTHER Restrictive RBC Transfusion Strategy

Trial Details

FieldValue
Enrollment Target 742 participants
Start Date 2018-02-12
Est. Completion 2024-08-22
Phase NA

What the Registry Record Tells You About NCT03309579

The ClinicalTrials.gov registry entry for NCT03309579 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 742 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ottawa Hospital Research Institute, which has 8 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Liberal RBC Transfusion Strategy is the first listed.

NCT03309579 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT03309579 about?

NCT03309579 is a clinical study titled "SAHaRA: A Randomized Controlled Trial". The SAHaRA trial will clarify the role of treating anemia with Red Blood Cell (RBC) transfusion in a unique and vulnerable patient population, and determine whether that impacts on functional outcomes and mortality. It will guide best practice standards and clarify the optimal RBC transfusion strate...

What is the current status of trial NCT03309579?

This trial is currently completed. It is a NA study. The enrollment target is 742 participants. The study started on 2018-02-12. Estimated completion is 2024-08-22.

What interventions are being tested in trial NCT03309579?

The interventions under investigation include: Liberal RBC Transfusion Strategy (OTHER), Restrictive RBC Transfusion Strategy (OTHER).

Who is sponsoring clinical trial NCT03309579?

This trial is sponsored by Ottawa Hospital Research Institute, which has 8 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.